Potential roles of GATA binding protein 5 in cardiovascular diseases

² The Center for Molecular Genetics of Cardiovascular Diseases, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, P. R. China

³ Shandong Provincial Sino-US Cooperation Research Center for Translational Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, P. R. China

⁴ Shandong Provincial Key Laboratory of Cardiac Disease Diagnosis and Treatment, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, P. R. China

^*Correspondence: yanbo@mail.jnmc.edu.cn (Bo Yan)

Rev. Cardiovasc. Med. 2020, 21(2), 253–261; https://doi.org/10.31083/j.rcm.2020.02.5104

Submitted: 10 December 2019 | Revised: 20 March 2020 | Accepted: 30 March 2020 | Published: 30 June 2020

This is an open access article under the CC BY 4.0 license http://creativecommons.org/licenses/by/4.0/.

Abstract

It is known that functional defects of GATA binding protein 5 (GATA5), an important member of GATA transcription factor family, could cause multiple congenital defects. However, the mechanisms of this transcription factor in cardiovascular diseases are still little known. Finding a genetic approach should help with understanding the possible roles of GATA5 in different cardiovascular diseases and purpose it as a possible therapeutic agent. Hence, this review is divided into three chapters to summarize the roles and main regulatory mechanisms of GATA5 in hypertension, arrhythmia and congenital heart disease, respectively. In each chapter, this review firstly introduces the roles of GATA5 mutations, and then discusses the main regulatory mechanisms of GATA5 in the corresponding diseases (Such as the endothelial dysfunction signaling pathway in the chapter of hypertension, GATA5-NaV1.5 signaling pathway in the chapter of arrhythmia, GATA5-HEY2 and GATA5-Nodal signaling pathway in the chapter of congenital heart disease). Additionally, based on these regulatory networks, it is also speculated that abnormal methylation of the GATA5 gene promoter may lead to cardiovascular diseases such as congenital heart disease. This conjecture is proposed to enrich the regulatory networks of GATA5 and provide a theoretical basis for diagnosis and treatment of cardiovascular diseases.

Keywords

GATA5

hypertension

arrhythmia

congenital heart disease

Figures

Figure 1.

Previous article in this issue

Next article in this issue

Rev. Cardiovasc. Med. Print ISSN 1530-6550 Electronic ISSN 2153-8174